JP2015529668A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015529668A5 JP2015529668A5 JP2015530008A JP2015530008A JP2015529668A5 JP 2015529668 A5 JP2015529668 A5 JP 2015529668A5 JP 2015530008 A JP2015530008 A JP 2015530008A JP 2015530008 A JP2015530008 A JP 2015530008A JP 2015529668 A5 JP2015529668 A5 JP 2015529668A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- asd
- level
- metabolites
- metabolite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000029560 autism spectrum disease Diseases 0.000 claims 39
- 239000002207 metabolite Substances 0.000 claims 29
- 238000000034 method Methods 0.000 claims 24
- 230000036765 blood level Effects 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 8
- 230000003542 behavioural effect Effects 0.000 claims 6
- 230000002496 gastric effect Effects 0.000 claims 6
- 206010003805 Autism Diseases 0.000 claims 4
- 208000020706 Autistic disease Diseases 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 4
- 108090000695 Cytokines Proteins 0.000 claims 4
- 230000003870 intestinal permeability Effects 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 244000005709 gut microbiome Species 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 239000006041 probiotic Substances 0.000 claims 3
- 230000000529 probiotic effect Effects 0.000 claims 3
- 235000018291 probiotics Nutrition 0.000 claims 3
- 238000003786 synthesis reaction Methods 0.000 claims 3
- RSTKLPZEZYGQPY-UHFFFAOYSA-N 3-(indol-3-yl)pyruvic acid Chemical compound C1=CC=C2C(CC(=O)C(=O)O)=CNC2=C1 RSTKLPZEZYGQPY-UHFFFAOYSA-N 0.000 claims 2
- 208000004998 Abdominal Pain Diseases 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 2
- 208000002881 Colic Diseases 0.000 claims 2
- 206010010774 Constipation Diseases 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 208000019902 chronic diarrheal disease Diseases 0.000 claims 2
- 230000009429 distress Effects 0.000 claims 2
- DUIFVCFSAWHIOD-AATRIKPKSA-N indolylacryloylglycine Chemical compound C1=CC=C2C(/C=C/C(=O)NCC(=O)O)=CNC2=C1 DUIFVCFSAWHIOD-AATRIKPKSA-N 0.000 claims 2
- 210000000936 intestine Anatomy 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 230000002485 urinary effect Effects 0.000 claims 2
- DWZGLEPNCRFCEP-UHFFFAOYSA-N 4-ethylphenyl sulfate Chemical compound CCC1=CC=C(OS(O)(=O)=O)C=C1 DWZGLEPNCRFCEP-UHFFFAOYSA-N 0.000 claims 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 241000606125 Bacteroides Species 0.000 claims 1
- 241000606124 Bacteroides fragilis Species 0.000 claims 1
- 241001112696 Clostridia Species 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 claims 1
- JJIHLJJYMXLCOY-BYPYZUCNSA-N N-acetyl-L-serine Chemical compound CC(=O)N[C@@H](CO)C(O)=O JJIHLJJYMXLCOY-BYPYZUCNSA-N 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000022379 autosomal dominant Opitz G/BBB syndrome Diseases 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- ZCKYOWGFRHAZIQ-UHFFFAOYSA-N dihydrourocanic acid Chemical compound OC(=O)CCC1=CNC=N1 ZCKYOWGFRHAZIQ-UHFFFAOYSA-N 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- WGNAKZGUSRVWRH-UHFFFAOYSA-M p-cresol sulfate(1-) Chemical compound CC1=CC=C(OS([O-])(=O)=O)C=C1 WGNAKZGUSRVWRH-UHFFFAOYSA-M 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261694679P | 2012-08-29 | 2012-08-29 | |
| US61/694,679 | 2012-08-29 | ||
| PCT/US2013/057148 WO2014036182A2 (en) | 2012-08-29 | 2013-08-28 | Diagnosis and treatment of autism spectrum disorder |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018168982A Division JP2019031497A (ja) | 2012-08-29 | 2018-09-10 | 自閉症スペクトラム障害の診断および処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015529668A JP2015529668A (ja) | 2015-10-08 |
| JP2015529668A5 true JP2015529668A5 (enExample) | 2016-10-20 |
| JP6679309B2 JP6679309B2 (ja) | 2020-04-15 |
Family
ID=50184623
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015530008A Active JP6679309B2 (ja) | 2012-08-29 | 2013-08-28 | 自閉症スペクトラム障害の診断および処置 |
| JP2018168982A Pending JP2019031497A (ja) | 2012-08-29 | 2018-09-10 | 自閉症スペクトラム障害の診断および処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018168982A Pending JP2019031497A (ja) | 2012-08-29 | 2018-09-10 | 自閉症スペクトラム障害の診断および処置 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10220089B2 (enExample) |
| EP (1) | EP2890808A4 (enExample) |
| JP (2) | JP6679309B2 (enExample) |
| CN (2) | CN114949001A (enExample) |
| AU (2) | AU2013308826B2 (enExample) |
| CA (1) | CA2881656C (enExample) |
| WO (1) | WO2014036182A2 (enExample) |
Families Citing this family (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| BR112013002667B1 (pt) | 2010-08-04 | 2020-02-04 | Thomas Julius Borody | composições para transplante da flora intestinal e métodos para fazê-las e usá-las e dispositivos para administrá-las |
| EP3610881A1 (en) | 2011-03-09 | 2020-02-19 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| US10039777B2 (en) | 2012-03-20 | 2018-08-07 | Neuro-Lm Sas | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
| US9719144B2 (en) | 2012-05-25 | 2017-08-01 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
| US10220089B2 (en) | 2012-08-29 | 2019-03-05 | California Institute Of Technology | Diagnosis and treatment of autism spectrum disorder |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| MX2016000293A (es) * | 2013-07-09 | 2016-06-21 | Stemina Biomarker Discovery Inc | Biomarcadores del trastrono del espectro autista. |
| US9176113B1 (en) * | 2014-04-11 | 2015-11-03 | Synapdx Corporation | Methods and systems for determining autism spectrum disorder risk |
| US20150294081A1 (en) | 2014-04-11 | 2015-10-15 | Synapdx Corporation | Methods and systems for determining autism spectrum disorder risk |
| US9758839B2 (en) | 2014-10-21 | 2017-09-12 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features |
| EP3209803A4 (en) | 2014-10-21 | 2018-06-13 | Ubiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics |
| US10265009B2 (en) | 2014-10-21 | 2019-04-23 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features |
| HK1244461A1 (zh) * | 2014-10-30 | 2018-08-10 | 加利福尼亚技术学院 | 用於改善神经发育障碍中的行为的包含细菌的组合物和方法 |
| WO2016069792A1 (en) * | 2014-10-30 | 2016-05-06 | California Institute Of Technology | Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders |
| EP3212207A4 (en) | 2014-10-30 | 2018-06-13 | California Institute of Technology | Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders |
| EP3193901B1 (en) | 2014-12-23 | 2018-04-04 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| ES2658310T3 (es) | 2014-12-23 | 2018-03-09 | 4D Pharma Research Limited | Una cepa de bacteroides thetaiotaomicron y su uso en la reducción de la inflamación |
| JP6611156B2 (ja) * | 2015-01-30 | 2019-11-27 | 史郎 栃谷 | 妊娠期母体腸内細菌攪乱による行動異常モデル動物の作製方法とその用途 |
| US10525020B2 (en) | 2015-02-11 | 2020-01-07 | Laboratory Corporation Of America Holdings | Metabolic markers of attention deficit hyperactivity disorder |
| EP3268354B1 (en) | 2015-03-13 | 2020-05-06 | Mironova Innovations, LLC | Nalpha, nalpha, nalpha-trialkyl histidine derivatives useful for the preparation of ergothioneine compounds |
| EP3283086A4 (en) * | 2015-04-13 | 2019-04-24 | Ubiome Inc. | METHOD AND SYSTEM FOR MICROBIOMY-DERIVED DIAGNOSTICS AND THERAPEUTIC FOR DISEASES RELATED TO MICROBIOMIC FUNCTIONAL PROPERTIES |
| AU2016248050A1 (en) * | 2015-04-13 | 2017-11-09 | Psomagen, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues |
| AU2016250102A1 (en) * | 2015-04-13 | 2017-11-09 | Psomagen, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features |
| CN107949391B (zh) | 2015-05-14 | 2021-11-09 | 克雷斯顿沃控股公司 | 用于粪便菌群移植的组合物以及用于制备和使用它们的方法和用于递送它们的装置 |
| PT3297644T (pt) * | 2015-05-22 | 2022-03-30 | Univ Arizona State | Métodos para tratar distúrbios do espetro do autismo e sintomas associados |
| TWI759266B (zh) | 2015-06-15 | 2022-04-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物之用途 |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA55434B1 (fr) | 2015-06-15 | 2022-02-28 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| PT3307288T (pt) | 2015-06-15 | 2019-10-17 | 4D Pharma Res Ltd | Composições compreendendo estirpes bacterianas |
| CN105213433A (zh) * | 2015-11-06 | 2016-01-06 | 王益超 | 一种用于治疗孤独症、复发性流产和不孕症的组合物 |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| MA45287A (fr) | 2015-11-20 | 2018-08-22 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| CN105543369B (zh) * | 2016-01-13 | 2020-07-14 | 金锋 | 精神障碍的生物标志物及其应用 |
| PT3313423T (pt) | 2016-03-04 | 2019-07-10 | 4D Pharma Plc | Composições que compreendem a estirpe blautia bacteriana para tratar a hipersensibilidade visceral |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| WO2017197252A1 (en) * | 2016-05-13 | 2017-11-16 | Stemina Biomarker Discovery, Inc. | Autism subsets |
| WO2017205302A1 (en) | 2016-05-23 | 2017-11-30 | California Institute Of Technology | Regulate gut microbiota to treat neurodegenerative disorders |
| US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| US10849936B2 (en) | 2016-07-01 | 2020-12-01 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| US20180036352A1 (en) | 2016-08-03 | 2018-02-08 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
| MX2019002918A (es) | 2016-09-16 | 2019-07-18 | Dyax Corp | Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto. |
| US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| US11213549B2 (en) | 2016-10-11 | 2022-01-04 | Finch Therapeutics Holdings Llc | Compositions and method for treating primary sclerosing cholangitis and related disorders |
| WO2018071537A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| WO2018089794A1 (en) * | 2016-11-11 | 2018-05-17 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods and compositions for changing metabolite levels in a subject |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| BR112018076609B1 (pt) * | 2016-12-15 | 2023-02-14 | Société des Produits Nestlé S.A. | Composição alimentícia para animais de estimação, seus usos, e métodos não terapêutico para modular a quantidade e para medição de uma alteração na quantidade de pelo menos uma dentre bifidobacterium, lactobacillus ou clostridium perfringens |
| EP3579924A4 (en) * | 2017-02-07 | 2020-12-23 | California Institute of Technology | MODULATION OF THE INTESTINAL MICROBIOTE IN HUNTINGTON'S DISEASE AND RETT SYNDROME |
| JP7324709B2 (ja) * | 2017-02-09 | 2023-08-10 | コグノア，インク． | デジタル個別化医療のためのプラットフォームとシステム |
| WO2018152133A1 (en) * | 2017-02-14 | 2018-08-23 | California Institute Of Technology | Modulation of microbial synthesis of 4-etylphenol and 4-ethylphenol sulfate in behavior and disease |
| EP3600349A4 (en) * | 2017-03-31 | 2020-09-30 | Axial Biotherapeutics, Inc. | SELECTIVE GUT SEQUESTRATION AGENTS FOR THE TREATMENT AND PREVENTION OF AUTISM AND RELATED DISORDERS |
| WO2018187464A1 (en) | 2017-04-05 | 2018-10-11 | Crestovo Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
| WO2018187467A1 (en) | 2017-04-05 | 2018-10-11 | Crestovo Holdings Llc | Compositions and methods for treating parkinson's disease (pd) and related disorders |
| WO2018213204A1 (en) | 2017-05-15 | 2018-11-22 | Axial Biotherapeutics, Inc. | Inhibitors of microbially induced amyloid |
| RS61872B1 (sr) | 2017-05-22 | 2021-06-30 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
| WO2018215782A1 (en) | 2017-05-24 | 2018-11-29 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| WO2018216912A1 (ko) * | 2017-05-26 | 2018-11-29 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 자폐증 진단방법 |
| WO2018218159A1 (en) | 2017-05-26 | 2018-11-29 | Crestovo Holdings Llc | Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same |
| JP6840272B2 (ja) | 2017-06-14 | 2021-03-10 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | 細菌株を含む組成物 |
| EP3638271B1 (en) | 2017-06-14 | 2020-10-14 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| RS63393B1 (sr) | 2017-06-14 | 2022-08-31 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
| US11883155B2 (en) | 2017-07-05 | 2024-01-30 | Yusuf Ozgur Cakmak | System for monitoring auditory startle response |
| US11141089B2 (en) * | 2017-07-05 | 2021-10-12 | Yusuf Ozgur Cakmak | System for monitoring auditory startle response |
| US10939862B2 (en) * | 2017-07-05 | 2021-03-09 | Yusuf Ozgur Cakmak | System for monitoring auditory startle response |
| AU2018253466B2 (en) | 2017-07-17 | 2019-03-28 | smartDNA Pty Ltd | Method of diagnosing a dysbiosis |
| US11865145B2 (en) | 2017-08-07 | 2024-01-09 | Finch Therapeutics Holdings Llc | Compositions and methods for maintaining and restoring a healthy gut barrier |
| US20230158084A1 (en) * | 2018-01-05 | 2023-05-25 | California Institute Of Technology | Probiotics, metabolites, and uses thereof |
| WO2019180263A2 (en) | 2018-03-22 | 2019-09-26 | Adare Pharmaceuticals Sas | New use of microbiological compositions |
| WO2020012467A2 (en) * | 2018-07-08 | 2020-01-16 | Yeda Research And Development Co. Ltd. | Person-specific assessment of probiotics responsiveness |
| US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
| CN109142744A (zh) * | 2018-07-26 | 2019-01-04 | 珠海中科先进技术研究院有限公司 | 一种自闭症谱系障碍诊断试剂盒 |
| CN113164527A (zh) | 2018-09-27 | 2021-07-23 | 芬奇治疗控股有限责任公司 | 用于治疗癫痫和相关障碍的组合物和方法 |
| CA3118790A1 (en) | 2018-11-06 | 2020-05-14 | Stalicla Sa | Metabolic profiling for the diagnosis of a subset of idiopathic autism spectrum disorder patients, asd phenotype 1 |
| US11676719B2 (en) * | 2018-12-20 | 2023-06-13 | Oregon Health & Science University | Subtyping heterogeneous disorders using functional random forest models |
| CN109706235A (zh) * | 2019-01-29 | 2019-05-03 | 广州康昕瑞基因健康科技有限公司 | 一种肠道微生物菌群的检测和分析方法及其系统 |
| CA3136303A1 (en) | 2019-04-05 | 2020-10-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Diagnostic for childhood risk of autism spectrum disorder |
| WO2020206443A1 (en) * | 2019-04-05 | 2020-10-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Metabolites as diagnostics for autism spectrum disorder in children with gastrointestinal symptoms |
| US20220373563A1 (en) * | 2019-04-23 | 2022-11-24 | Peking Union Medical College Hospital | Machine learning-based autism spectrum disorder diagnosis method and device using metabolite as marker |
| EP3965820A4 (en) | 2019-05-07 | 2023-02-08 | The Regents of the University of California | COMPOSITIONS AND METHODS TO PROMOTE HEALTHY NEURAL DEVELOPMENT IN AN UNBORN BABY |
| CN110178787B (zh) * | 2019-05-08 | 2022-03-22 | 河南中医药大学 | 一种运用粪菌移植法建立自闭症大鼠模型的方法 |
| PE20221399A1 (es) | 2019-07-19 | 2022-09-15 | Finch Therapeutics Holdings Llc | Metodos y productos para el tratamiento de trastornos gastrointestinales |
| EP4041265A4 (en) * | 2019-10-11 | 2024-03-27 | Stemina Biomarker Discovery, Inc. | DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDERS ASSOCIATED WITH ALTERED LEVELS OF METABOLITES CONCENTRATIONS |
| TWI870485B (zh) | 2019-10-21 | 2025-01-21 | 日商表飛鳴製藥股份有限公司 | 多形類桿菌６０３０之用途 |
| US20230026402A1 (en) * | 2019-10-22 | 2023-01-26 | Cornell University | Microbiota based therapies to promote mental health |
| WO2021126220A1 (en) * | 2019-12-19 | 2021-06-24 | Hill's Pet Nutrition, Inc. | Compositions and methods of treating and reducing risk of conditions associated with elevated 4-ethylphenyl sulfate in canines using tomato pomace and methods of identifying canines at risk of such conditions |
| US20230145281A1 (en) * | 2020-03-06 | 2023-05-11 | University Of Virginia Patent Foundation | System and method for predicting risk of diagnosis for autism spectrum disorder using neonatal analytics |
| CN111455076B (zh) * | 2020-04-17 | 2022-10-21 | 济南市儿童医院 | 用于儿童孤独症评估的口腔菌群微生物 |
| CN116547520A (zh) * | 2020-09-21 | 2023-08-04 | 分子优公司 | 孤独症谱系障碍的诊断与治疗方法 |
| KR20230074216A (ko) * | 2020-09-21 | 2023-05-26 | 몰레큘러 유 코포레이션 | 자폐 스펙트럼 장애의 진단 및 치료 방법 |
| CN117083062A (zh) * | 2020-10-19 | 2023-11-17 | 第二基因组公司 | 用于治疗孤独症谱系障碍的方法 |
| CN114544826B (zh) * | 2020-11-24 | 2023-12-08 | 重庆医科大学 | 检测血浆中组氨酸的试剂在制备抑郁症检测试剂盒中的用途 |
| EP4012414A1 (en) | 2020-12-11 | 2022-06-15 | Stalicla S.A. | Diagnosis of autism spectrum disorder phenotype 1 |
| CN113069469B (zh) * | 2021-04-07 | 2022-12-13 | 上海市精神卫生中心（上海市心理咨询培训中心） | 调节性t细胞在制备治疗孤独症药物或细胞疗法中的应用 |
| CN114699423B (zh) * | 2022-02-16 | 2023-06-23 | 广州知易生物科技有限公司 | 脆弱拟杆菌的荚膜多糖提取物在制备防治精神分裂症的药物中的应用 |
| CN114699424B (zh) * | 2022-02-16 | 2023-07-18 | 广州知易生物科技有限公司 | 脆弱拟杆菌两性离子荚膜多糖或/和改性的两性离子荚膜多糖的新应用 |
| CN114457153A (zh) * | 2022-03-15 | 2022-05-10 | 西安交通大学 | 一种孤独症血清神经元来源外泌体标志物chrm1的应用 |
| CN117598247A (zh) * | 2022-03-25 | 2024-02-27 | 天津中医药大学 | 咪唑丙酸在制备用于诱导溃疡性结肠炎动物模型的造模剂中的应用 |
| CN114622026B (zh) * | 2022-04-02 | 2024-10-01 | 中南大学湘雅三医院 | 拟杆菌作为预测自闭症疗效的客观指标 |
| CN116990395A (zh) * | 2022-04-26 | 2023-11-03 | 中国科学院深圳先进技术研究院 | 一种基于粪便的阿尔兹海默症生物标志物及其应用 |
| CN115368300B (zh) * | 2022-10-27 | 2023-03-24 | 北京拓领博泰生物科技有限公司 | 用于tlr8抑制剂的化合物及其制备方法、应用 |
| CN115616227B (zh) * | 2022-11-18 | 2023-05-16 | 四川大学华西医院 | 吲哚-3-丙烯酰甘氨酸检测试剂的用途、诊断或辅助诊断慢性阻塞性肺病的试剂盒及系统 |
| US12005044B1 (en) | 2022-11-29 | 2024-06-11 | Autism Therapeutics Inc. | Treatment of autism spectrum disorders with ergothioneine, selenoneine, or combinations thereof |
| WO2025007066A1 (en) * | 2023-06-30 | 2025-01-02 | University Of Massachusetts | Biomarkers and methods related to fragile x syndrome |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5443826A (en) | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli |
| AUPM864894A0 (en) | 1994-10-07 | 1994-11-03 | Borody, Thomas Julius | Treatment of bowel-dependent neurological disorders |
| US5951977A (en) | 1997-10-14 | 1999-09-14 | The United States Of America, As Represented By The Secretary Of Agriculture | Competitive exclusion culture for swine |
| US20020013270A1 (en) | 2000-06-05 | 2002-01-31 | Bolte Ellen R. | Method for treating a mental disorder |
| US20040170617A1 (en) | 2000-06-05 | 2004-09-02 | Finegold Sydney M. | Method of treating diseases associated with abnormal gastrointestinal flora |
| AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| US20040005304A1 (en) | 2002-07-08 | 2004-01-08 | Mak Wood, Inc. | Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions |
| US8192733B2 (en) | 2003-08-29 | 2012-06-05 | Cobb & Associates | Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions |
| US7749509B2 (en) | 2003-08-29 | 2010-07-06 | Cobb And Company, Llp | Treatment of autism using probiotic composition |
| US7731976B2 (en) | 2003-08-29 | 2010-06-08 | Cobb And Company, Llp | Treatment of irritable bowel syndrome using probiotic composition |
| US20060177424A1 (en) | 2003-08-29 | 2006-08-10 | Cobb Mark L | Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions |
| CA2586334A1 (en) | 2004-11-16 | 2006-06-08 | Neurochem (International) Limited | Compounds for the treatment of cns and amyloid associated diseases |
| GB0504096D0 (en) | 2005-02-28 | 2005-04-06 | Tipogen As | Method |
| US20100233312A9 (en) | 2005-04-11 | 2010-09-16 | The Procter & Gamble Company | Compositions comprising probiotic and sweetener components |
| ES2473625T3 (es) | 2007-10-26 | 2014-07-07 | Brenda E. Moore | Composición probi�tica y métodos para inducir y mantener la pérdida de peso |
| DK2220030T3 (en) | 2007-11-06 | 2016-04-11 | Edison Pharmaceuticals Inc | 4- (P-QUINONYL) -2-HYDROXYBUTANAMIDDERIVATER TO TREAT mitochondrial |
| CA2711608A1 (en) | 2008-01-09 | 2009-07-16 | Yale University | Mutations in contaction associated protein 2 (cntnap2) are associated with increased risk for ideopathic autism |
| EP2358370A2 (en) | 2008-11-13 | 2011-08-24 | Link Medicine Corporation | Treatment of proteinopathies using a farnesyl transferase inhibitor |
| WO2010111516A2 (en) | 2009-03-25 | 2010-09-30 | Whitehead Institute For Biomedical Research | Compositions and methods for inhibiting biofilms |
| US9050276B2 (en) * | 2009-06-16 | 2015-06-09 | The Trustees Of Columbia University In The City Of New York | Autism-associated biomarkers and uses thereof |
| US20110081320A1 (en) * | 2009-10-06 | 2011-04-07 | Nubiome, Inc. | Treatment/Cure of Autoimmune Disease |
| JP2013507394A (ja) | 2009-10-09 | 2013-03-04 | プロセラ インコーポレイテッド | 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法 |
| CA2797787C (en) * | 2010-04-29 | 2019-07-09 | Wisconsin Alumni Research Foundation | Metabolic biomarkers of autism |
| US9707207B2 (en) | 2010-05-26 | 2017-07-18 | The United States Of America As Represented By The Department Of Veterans Affairs | Method for diagnosing, preventing, and treating neurological diseases |
| WO2011153226A2 (en) | 2010-06-01 | 2011-12-08 | Moore Research Enterprises Llc | Cellular constituents from bacteroides, compositions thereof, and therapeutic methods employing bacteroides or cellular constituents thereof |
| US20130115257A1 (en) | 2010-07-08 | 2013-05-09 | Katholieke Universiteit Leuven | Compositions and methods for removal or destruction of amyloid fibril or amyloid adhesin comprising aggregates |
| JP5931884B2 (ja) * | 2010-10-07 | 2016-06-08 | カリフォルニア インスティチュート オブ テクノロジー | 自閉症の生菌療法 |
| US20120237482A1 (en) | 2011-03-18 | 2012-09-20 | Juan Rodriguez | Methods for treatment of neurological disorders by modulation of microglial activation |
| EP3569690B1 (en) | 2011-12-01 | 2024-08-28 | The University of Tokyo | Human-derived bacteria that induce proliferation or accumulation of regulatory t cells |
| US20150265661A1 (en) | 2012-04-13 | 2015-09-24 | Trustees Of Boston College | Prebiotic effect of sialyllactose |
| US10220089B2 (en) * | 2012-08-29 | 2019-03-05 | California Institute Of Technology | Diagnosis and treatment of autism spectrum disorder |
| KR102222273B1 (ko) | 2013-02-04 | 2021-03-08 | 세레스 테라퓨틱스, 인코포레이티드 | 조성물 및 방법 |
| WO2014121304A1 (en) | 2013-02-04 | 2014-08-07 | Seres Health, Inc. | Compositions and methods |
| US9511100B2 (en) | 2013-06-05 | 2016-12-06 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
| FI127671B (en) | 2014-05-28 | 2018-11-30 | Filip Scheperjans | Method for diagnostics of Parkinson’s disease |
| CN104546932A (zh) | 2014-09-30 | 2015-04-29 | 深圳华大基因科技有限公司 | 卵形拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用 |
| HK1244461A1 (zh) | 2014-10-30 | 2018-08-10 | 加利福尼亚技术学院 | 用於改善神经发育障碍中的行为的包含细菌的组合物和方法 |
| EP3212207A4 (en) | 2014-10-30 | 2018-06-13 | California Institute of Technology | Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders |
| WO2016069792A1 (en) | 2014-10-30 | 2016-05-06 | California Institute Of Technology | Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders |
| US20170360853A1 (en) | 2015-01-07 | 2017-12-21 | Ecole Polytechnique Federale De Lausanne (Epfl) | Gastro-Intestinal Biomarkers for Diagnosis and Therapies of Proteinopathies |
| PT3297644T (pt) | 2015-05-22 | 2022-03-30 | Univ Arizona State | Métodos para tratar distúrbios do espetro do autismo e sintomas associados |
| WO2017205302A1 (en) | 2016-05-23 | 2017-11-30 | California Institute Of Technology | Regulate gut microbiota to treat neurodegenerative disorders |
| US11324717B2 (en) | 2016-06-22 | 2022-05-10 | Microbial Research Management Health Nv | Microbial carotenoids affecting gut microbial composition |
-
2013
- 2013-08-28 US US14/012,769 patent/US10220089B2/en active Active
- 2013-08-28 WO PCT/US2013/057148 patent/WO2014036182A2/en not_active Ceased
- 2013-08-28 JP JP2015530008A patent/JP6679309B2/ja active Active
- 2013-08-28 AU AU2013308826A patent/AU2013308826B2/en active Active
- 2013-08-28 CN CN202210623110.8A patent/CN114949001A/zh active Pending
- 2013-08-28 EP EP13832132.8A patent/EP2890808A4/en active Pending
- 2013-08-28 CN CN201380056909.2A patent/CN104768560A/zh active Pending
- 2013-08-28 CA CA2881656A patent/CA2881656C/en active Active
-
2018
- 2018-09-10 JP JP2018168982A patent/JP2019031497A/ja active Pending
- 2018-11-16 US US16/193,724 patent/US11052151B2/en active Active
-
2019
- 2019-07-18 AU AU2019206081A patent/AU2019206081B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015529668A5 (enExample) | ||
| Shi et al. | Supplement of microbiota-accessible carbohydrates prevents neuroinflammation and cognitive decline by improving the gut microbiota-brain axis in diet-induced obese mice | |
| Miquel et al. | Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models | |
| Lui et al. | Diagnosis and management of noncardiac complications in adults with congenital heart disease: a scientific statement from the American Heart Association | |
| Jain et al. | Serum endotoxin, inflammatory mediators, and magnetic resonance spectroscopy before and after treatment in patients with minimal hepatic encephalopathy | |
| JP6679309B2 (ja) | 自閉症スペクトラム障害の診断および処置 | |
| Baumann et al. | Biliary atresia | |
| Camacho et al. | The gastrointestinal dysfunction scale for Parkinson's disease | |
| WO2006050479A3 (en) | Compositions and methods for diagnosing colon disorders | |
| Iwasa et al. | Pathophysiology and management of hepatic encephalopathy 2014 update: ammonia toxicity and hyponatremia | |
| BR112014014960A2 (pt) | métodos para o diagnóstico da doença de alzheimer | |
| BR112012016767A2 (pt) | Método para diagnosticar se um paciente sofre de uma condição hepática ou do fígado, método para detectar o desenvolvimento de uma patologia do fígado, método para deter5 minar o risco de um paciente para uma condição do fígado e sistema para diagnosticar o estado de saúde hepática | |
| Erdogan et al. | Optimal testing for diagnosis of fructose intolerance: over-dosage leads to false positive intolerance test | |
| Khvorykh et al. | The comparison of searching strategies for genes related to is-chemic stroke: case-control Human and model animal studies | |
| Patel et al. | Congenital hepatic fibrosis associated with polycystic kidney disease | |
| Hansen | Does Late-in-Life Aerobic Exercise Training Alter the Relative Abundance of the Murine Intestinal Microbiota? | |
| Norenberg et al. | P: 78 Mechanism of Alzheimer Type II Astrocyte Development: Implication for the Defective Neuronal Integrity and Neurobehavioral Deficits Associated With Chronic Hepatic Encephalopathy | |
| Hayhoe et al. | Cachexia, Sarcopenia and Muscle Wasting, Maastricht, The Netherlands, 7–9 December 2018 | |
| Menon et al. | 54.: Regulatory T cells in amyotrophic lateral sclerosis: A role for disease modulation? | |
| Potvin-Jutras et al. | Longitudinal effects of cerebrovascular reactivity and cerebral pulsatility in cognitively intact older adults with APOE4: links with cognition | |
| Ochoa-Sanchez et al. | P: 82 Genetically engineered E. coli Nissle attenuates hyperammonemia and improves memory in an experimental model of cirrhosis and hepatic encephalopathy | |
| WO2023154966A1 (en) | Compositions and methods for sequestering metabolites in the gastrointestinal tract | |
| Czopik et al. | miR147 promotes mucosal integrity and healing in intestinal inflammation | |
| Korovaichuk et al. | P: 7 Identifying overt hepatic encephalopathy using administrative data in the ICD-10 era: a study to validate diagnostic algorithms | |
| Furnari et al. | Fecal calprotectin in systemic sclerosis: light and shade of a promising tool |